For decades, scientists warned of the potential for a global coronavirus outbreak. But when SARS-CoV-2 emerged, no therapeutics, drugs, or vaccines were readily available. The Rapidly Emerging Antiviral Drug Development Initiative (READDI) — founded by researchers at UNC and the Structural Genomics Consortium — is not only finding solutions to the COVID-19 pandemic, but also drugs and therapeutics for future viral outbreaks.
Anna Cliffe is a postdoctoral research fellow in the UNC Neuroscience Center in the School of Medicine. Her research focuses on the herpes simplex virus (HSV) and the effect stress has on reactivation of the virus.
UNC School of Medicine’s William Valdar and James Crowley lead a quest to discover the genetic underpinnings of drug side effects.